RetaLABS Research Team

Who we are

The RetaLABS Research Team is an editorial collective, not a single named author. Articles are produced and reviewed by a small group of researchers and writers with backgrounds in peptide pharmacology, metabolic-disease literature, and clinical trial interpretation. The team operates anonymously by design — this aligns with the privacy-first posture of the broader RetaLABS operation, which accepts only cryptocurrency payment, ships in unmarked packaging, and uses the .is country-code domain specifically because anonymity is a deliberate choice rather than a workaround.

Collective bylines are an accepted pattern in research and editorial publishing (for example "Reuters Staff", "The Economist Briefing Team", "WIRED Staff"). They describe institutional authorship — the standards and review process are the accountability mechanism, not an individual reputation. This page documents those standards so the basis for that institutional authorship is open to scrutiny.

Editorial methodology

Every research article on RetaLABS follows the same four-step production process:

1. Source identification. Primary clinical trial publications (NEJM, JAMA, Lancet, Nature Metabolism, Diabetes Care) and ClinicalTrials.gov registrations are the default sources for quantitative claims. Secondary sources (review articles, conference abstracts) are used for context only, never for primary numerical claims.
2. Drafting. Articles are drafted with explicit references to source documents (DOI-linked when published with a DOI) and explicit dose, duration, and population context for every trial outcome cited. Cross-trial comparisons are flagged as such; no head-to-head trial result is described as comparative unless it was a controlled head-to-head study.
3. Internal review. A second team member reviews each article before publication. The review checks that every numerical claim has a citable source, that no therapeutic claim is made about research-use-only compounds, and that the article does not conflate research-grade peptides with approved therapeutic versions of related molecules.
4. Publication and revalidation. Articles publish with explicit publishedAt and updatedAt dates exposed in both the visible byline and the Article schema. Older articles are revalidated when relevant new trial data, regulatory updates, or ClinicalTrials.gov status changes occur.

Sources policy

Sources used in RetaLABS research articles, in order of preference:

• Peer-reviewed primary clinical trial publications. NEJM, JAMA, Lancet, Nature Metabolism, Diabetes Care, Diabetes Obesity & Metabolism. These are the authoritative source for trial methodology, dose, duration, primary endpoint, safety profile, and population demographics.
• Registry data. ClinicalTrials.gov NCT identifiers are cited for trial design, enrolment, status, and active site lists for ongoing Phase 3 studies that have not yet published.
• Mechanistic and pharmacokinetic literature. Peer-reviewed pharmacology publications, including the original receptor-binding characterisation studies for each compound (e.g. Coskun et al., Nature Metabolism 2022 for retatrutide).
• Regulatory references. TGA (Australia), FDA (United States), EMA (European Union) for product approval status and regulatory framework. The TGA Australian Register of Therapeutic Goods is the authoritative source for the Australian approval status of any compound referenced.
• Sponsor disclosure. Eli Lilly, Novo Nordisk, and other compound developers' published pipeline updates and investor briefings, used as the current source for Phase 3 enrolment numbers and readout timing.

Sources we deliberately do not use as primary references: marketing copy from other vendors, social media posts, anecdotal reports, anonymous forum discussion, and pre-print servers (acceptable as context but never for primary numerical claims).

Update policy

Research articles are reviewed for accuracy on the following triggers:

• New peer-reviewed publication. When a relevant trial publishes (e.g. a TRIUMPH Phase 3 readout), affected articles are updated within 14 days of publication, with the updatedAt date and the substantive change reflected in the next published version.
• Regulatory status change. TGA, FDA, or EMA approval changes for any compound referenced on the site are reflected within 7 days.
• ClinicalTrials.gov status change. Changes to active enrolment, expected primary completion dates, or status of any cited trial are reflected at the next monthly revalidation cycle.
• Reader-flagged factual issue. Errors flagged by researchers via support@retalabs.is are reviewed and either corrected or the source of the disputed claim cited, typically within 5 business days.

Every article displays its Updated date in the byline header, derived from the same data source as the Article schema's dateModified.

Conflict of interest disclosure

RetaLABS is a commercial supplier of research-grade peptides. Research articles published on this site discuss compounds that the supplier sells. This is a commercial conflict of interest and we disclose it openly here so the conflict is not hidden behind the editorial separation between research articles and product pages.

We address this conflict structurally:

• Numerical claims are sourced. Every trial efficacy, safety, or pharmacology number is sourced to an independent peer-reviewed publication or trial registry. Researchers can verify each claim against the underlying source.
• No therapeutic claims. Articles describe research findings from clinical trials. They do not make therapeutic claims about research-grade peptides supplied for laboratory use, because those compounds are not approved as therapeutics in Australia.
• No inter-product positioning. Comparison articles compare compounds based on published trial data — not based on which compound RetaLABS happens to stock at higher margin. Where multiple RetaLABS-stocked compounds are compared, the published research is the determinant.
• No comparison to approved therapeutic versions. Research-grade peptides supplied by RetaLABS for laboratory research are structurally and pharmacologically related to therapeutic products approved elsewhere, but they are supplied through a separate channel and are not the same product as approved therapeutic versions. Articles do not position research-grade supply as a substitute for approved therapeutic versions.

Contact and corrections

For factual corrections, source-verification questions, or methodology queries, email support@retalabs.is. Include the URL of the article and the specific claim under review. Confirmed factual errors are corrected and reflected in the article's updatedAt date.